This information was released for public disclosure on March 17, 2016 at 08.20 am CET.
CellaVision AB (public) today announced that its Nomination Committee has proposed the election of Sören Mellstig as new Chairman of the Board and re-election of Christer Fåhraeus, Åsa Hedin, Roger Johanson, Torbjörn Kronander, Anna Malm Bernsten and Niklas Prager as Directors of the Board.
Lars Gatenbeck who served as Chairman of the Board for the last 14 years has declined re-election to the post at the Annual General Meeting (AGM) on May 4, 2016. Lars Gatenbeck's leadership, together with the board and management, have resulted in the development of the company from being in a start-up phase to become a global market leading diagnostic company, listed on the Nasdaq OMX Stockholm, Small Cap, with a market capitalization well in excess of SEK one billion.
"It has been an amazing journey to see CellaVision develop over the years. Focus and hard work has led to the position we have today, and I am proud of what we have achieved," says Lars Gatenbeck.
The Nomination Committee proposes the election of Sören Mellstig as new Chairman of the Board at the AGM in May. Sören holds several senior positions today, including Chairman of the Board at Trelleborg AB (publ), Ellevio AB, AB and Textilia MD Ferrosan A/S. Sören's career includes various managerial positions at Akzo Nobel, CFO and Vice President of Incentive, CFO, President and finally President and CEO of Gambro in the years of 2000-2006.
The Nomination Committee consists of the four largest shareholders represented by Nominatoion Committee Chairman Christer Fåhraeus (appointed by Christer Fåhraeus and companies), Bo Lundgren (appointed by Swedbank Robur Funds), Astrid Samuelsson (appointed by Handelsbanken Funds), Joel Eklund (appointed by Eklund & Peterson AB) and the Chairman of the Board Lars Gatenbeck.
"The Nominating Committee is pleased to propose Sören Mellstig as the new Chairman of the Board at CellaVision. Sören has a broad experience within medical technology, not least from his years at Gambro. His previous assignments have included leading and building companies in several sectors which will bring valuable perspectives to CellaVision's development and strategic work, "says Christer Fåhraeus, founder and largest shareholder in CellaVision.
The Nomination Committee's proposal for Board members:
- Sören Mellstig - Chairman of the Board
- Christer Fåhraeus - Board Member
- Åsa Hedin - Board Member
- Roger Johanson - Board Member
- Torbjörn Kronander - Board Member
- Anna Malm Bernsten - Board Member
- Niklas Prager - Board Member
For more information, please contact:
Christer Fåhraeus, Chairman of the Nomination Committee, CellaVision AB
Tel: +46 (0) 705-60 90 00 | E-mail: cf@flatfrog.com
Christer Fåhraeus, Chairman of the Nomination Committee, CellaVision AB
Tel: +46 (0) 705-60 90 00 | E-mail: cf@flatfrog.com
Lars Gatenbeck, Chairman of the Board, CellaVision AB
Tel: +46 (0) 70- 535 44 44 | Email: lars.gatenbeck@lifeequity.se
Tel: +46 (0) 70- 535 44 44 | Email: lars.gatenbeck@lifeequity.se
About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the mother company in Lund and by the market support organizations in the US, Canada, China and Japan. In 2015 sales were SEK 239 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the mother company in Lund and by the market support organizations in the US, Canada, China and Japan. In 2015 sales were SEK 239 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com
